You are here

Pfizer

Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals

Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals

Fierce Pharma

Flag link:

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

BioCentury

acute kidney injury

Flag link:

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Fierce Pharma

Gilead Sciences

Flag link:

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Fierce Pharma

Adamis Pharmaceuticals

Flag link:

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Endpoints

Flag link:

Sangamo backs up early success for hemophilia gene therapy

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Spark Therapeutics

Flag link:

Elizabeth Warren blasts former FDA commissioner for joining Pfizer’s board

Elizabeth Warren blasts former FDA commissioner for joining Pfizer’s board

Stat

Elizabeth Warren

Flag link:

Pfizer’s gamble on a new lease on life for aging sildenafil franchise fizzles in PhIII

Pfizer’s gamble on a new lease on life for aging sildenafil franchise fizzles in PhIII

Endpoints

Flag link:

Two years into dance, BEACON data clinched Pfizer-Array deal

Two years into dance, BEACON data clinched Pfizer-Array deal

BioCentury

Array Biopharma

Flag link:

Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Yahoo/Zacks.com

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Pfizer's About to Enter a Sales Slump

Pfizer's About to Enter a Sales Slump

Motley Fool

Flag link:

Another Biosimilar Approval From FDA, Another Unknown Launch Date

Another Biosimilar Approval From FDA, Another Unknown Launch Date

RAPS.org

Flag link:

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

Endpoints

Flag link:

U.S. advisory panel stops short of broad recommendations for two common vaccines

U.S. advisory panel stops short of broad recommendations for two common vaccines

Stat

advisory panels

Flag link:

These 3 Biotech Stocks Skyrocketed Last Week

These 3 Biotech Stocks Skyrocketed Last Week

Motley Fool

Array Biopharma

G1 Therapeutics

Flag link:

GSK consumer health sell-off ahead of Pfizer joint venture

GSK consumer health sell-off ahead of Pfizer joint venture

Pharmaforum

consumer health

Flag link:

Array-size deals don’t come around too often

Array-size deals don’t come around too often

EP Vantage

Array Biopharma

Flag link:

3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal

3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal

Motley Fool

Array Biopharma

Gilead Sciences

Flag link:

Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

Motley Fool

Array Biopharma

Flag link:

Pages